Capecitabine/cyclophosphamide combination therapy for patients with advanced or metastatic breast cancer who have been previously treated with anthracyclines - a phase 2 study
Phase 2
- Conditions
- Breast cancer
- Registration Number
- JPRN-C000000022
- Lead Sponsor
- Kyushu Breast Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1)Pregnant or breast feeding 2)Documented history of serious hypersensitivity reaction on the medical drugs 3)Patients who have experienced prior chemotherapy with capecitabine 4)With metastasis to the central nervous system 5)Serious underlying medical illness with heart, gastrointestinal tract, or infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Progression-free survival(PFS), overall survival(OS), adverse event